![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: ETNPPL |
Gene summary for ETNPPL |
![]() |
Gene information | Species | Human | Gene symbol | ETNPPL | Gene ID | 64850 |
Gene name | ethanolamine-phosphate phospho-lyase | |
Gene Alias | AGXT2L1 | |
Cytomap | 4q25 | |
Gene Type | protein-coding | GO ID | GO:0005575 | UniProtAcc | Q8TBG4 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
64850 | ETNPPL | HCC1_Meng | Human | Liver | HCC | 3.22e-05 | -1.05e-02 | 0.0246 |
64850 | ETNPPL | HCC2 | Human | Liver | HCC | 3.08e-17 | 3.10e+00 | 0.5341 |
64850 | ETNPPL | S028 | Human | Liver | HCC | 1.15e-03 | 2.85e-01 | 0.2503 |
64850 | ETNPPL | S029 | Human | Liver | HCC | 1.72e-08 | 5.05e-01 | 0.2581 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Liver | ![]() | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Thyroid | PTC | ![]() |
Thyroid | goiters | ![]() |
Thyroid | ATC | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
ETNPPL | SNV | Missense_Mutation | c.574N>A | p.Glu192Lys | p.E192K | Q8TBG4 | protein_coding | deleterious(0.03) | possibly_damaging(0.899) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
ETNPPL | SNV | Missense_Mutation | c.470G>A | p.Gly157Glu | p.G157E | Q8TBG4 | protein_coding | deleterious(0.02) | possibly_damaging(0.862) | TCGA-BH-A0H5-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | CR | |
ETNPPL | SNV | Missense_Mutation | c.667N>T | p.Ile223Phe | p.I223F | Q8TBG4 | protein_coding | tolerated(0.17) | probably_damaging(0.978) | TCGA-D8-A1XL-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicine+cyclophosphamide+tamoxifen | SD | |
ETNPPL | SNV | Missense_Mutation | c.1013N>C | p.Arg338Thr | p.R338T | Q8TBG4 | protein_coding | tolerated(0.38) | benign(0.021) | TCGA-E2-A1IN-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | arimidex | SD | |
ETNPPL | SNV | Missense_Mutation | rs753218203 | c.280C>T | p.Arg94Cys | p.R94C | Q8TBG4 | protein_coding | deleterious(0.01) | benign(0.299) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
ETNPPL | SNV | Missense_Mutation | c.1270N>C | p.Phe424Leu | p.F424L | Q8TBG4 | protein_coding | tolerated(0.77) | benign(0) | TCGA-FU-A3HZ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
ETNPPL | SNV | Missense_Mutation | novel | c.777N>G | p.Phe259Leu | p.F259L | Q8TBG4 | protein_coding | deleterious(0) | possibly_damaging(0.887) | TCGA-JW-A5VL-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
ETNPPL | SNV | Missense_Mutation | c.982N>C | p.Glu328Gln | p.E328Q | Q8TBG4 | protein_coding | deleterious(0.03) | possibly_damaging(0.756) | TCGA-JX-A3Q0-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Unknown | Unknown | SD | |
ETNPPL | SNV | Missense_Mutation | novel | c.442N>A | p.Glu148Lys | p.E148K | Q8TBG4 | protein_coding | deleterious(0) | possibly_damaging(0.811) | TCGA-ZJ-AAXU-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
ETNPPL | SNV | Missense_Mutation | novel | c.1061N>G | p.His354Arg | p.H354R | Q8TBG4 | protein_coding | deleterious(0.04) | possibly_damaging(0.652) | TCGA-A6-2672-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
Page: 1 2 3 4 5 6 7 8 9 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |